Timely Referral for Pediatric HSCT: A Key to Better Outcomes

11 April 2025

For children with certain life-threatening conditions like leukaemia, severe aplastic anaemia, or inherited immune disorders etc. Hematopoietic Stem Cell Transplantation (HSCT) can be a lifesaving treatment. However, the success of HSCT heavily depends on timely referral to a specialised transplant centre.

Why Timely Referral Matters

Better Survival Rates: Early referral allows optimal pre-transplant evaluation, donor selection, and conditioning, improving engraftment and reducing complications. 

Reduced Disease Progression: Delayed referral may lead to advanced disease, infections, or organ damage, making transplantation riskier. 

More Donor Options: Early referral increases the chances of finding a well-matched donor (matched family, unrelated), improving outcomes.

When to Refer?

Consider early referral for: 

  • Transfusion dependent anemias (e.g. Thalassemia, Sickle cell anemia).
  • High-risk leukemias or relapsed leukemias or lymphomas. 
  • Inborn error of immunities (e.g., SCID).
  • Bone marrow failure syndromes- Congenital (e.g., Fanconi anaemia) or acquired.
  • Certain metabolic disorders (e.g., Hurler syndrome).

Takeaways

Your early suspicion and prompt referral can make a critical difference as a practitioner. If a child has persistent cytopenias, recurrent infections, or a known genetic disorder, consult a pediatric haematologist/oncologist without delay.

Timely HSCT can turn a fatal diagnosis into a survivable condition—your awareness saves lives!

- Medically reviewed by Dr. Amit Jain (Consultant Pediatric Hematology-Oncology & Pediatric Bone Marrow Transplant)

Facebook
Twitter
LinkedIn
Email
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male